title: Treatment-related cardiotoxicity in survivors of childhood cancer.
abstract: Treatment advances and higher participation rates in clinical trials have rapidly increased the number of survivors of childhood cancer. However, chemotherapy and radiation treatments are cardiotoxic and can cause cardiomyopathy, conduction defects, myocardial infarction, hypertension, stroke, pulmonary oedema, dyspnoea and exercise intolerance later in life. These cardiotoxic effects are often progressive and irreversible, emphasizing a need for effective prevention and treatment to reduce or avoid cardiotoxicity. Medical interventions, such as angiotensin-converting enzyme inhibitors, β-blockers, and growth hormone therapy, might be used to treat cardiotoxicity in childhood cancer survivors. Preventative strategies should include the use of dexrazoxane, which provides cardioprotection without reducing the oncological efficacy of doxorubicin chemotherapy; less-toxic anthracycline derivatives and the use of antioxidant nutritional supplements might also be beneficial. Continuous-infusion doxorubicin provides no benefit over bolus infusion in children. Identifying patient-related (for example, obesity and hypertension) and drug-related (for example, cumulative dose) risk factors for cardiotoxicity could help tailor treatments to individual patients. However, all survivors of childhood cancer are at increased risk of cardiotoxicity, suggesting that survivor screening recommendations for assessment of global risk of premature cardiovascular disease should apply to all survivors. Optimal, evidence-based monitoring strategies and multiagent preventative treatments still need to be identified.
authors.affiliation: Department of Pediatrics, Wayne State University School of Medicine and Children's Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, MI 48201, USA.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Lipshultz
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Cochran
authors.forename: Vivian I
authors.initials: VI
authors.lastname: Franco
authors.forename: Tracie L
authors.initials: TL
authors.lastname: Miller
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced*; D002648:Child; D006321:Heart / Q000187:drug effects* / Q000528:radiation effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011832:Radiation Injuries / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects*; D012307:Risk Factors; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents